Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: A Belgian consensus report

Acta Clinica Belgica

Volumn 60, Issue 6, 2005, Pages 329-337

  Peetermans, W E ^a   Van De Vyver, N ^b   Van Laethem, Y ^c   Van Damme, P ^d   Thiry, N ^d   Trefois, P ^e   Geerts, P ^f   Schetgen, M ^g   Peleman, R ^h   Swennen, B ⁱ   Verhaegen, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Scientific Society of General Practitioners of Flanders (WVVH)   (Belgium)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Scientific Society of General Practitioners of the French Community (SSMG)   (France)

^f Omtrent Gezondheid Question Santé ^*

^g FREE UNIVERSITY OF BRUSSELS   (Belgium)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ High Council for Public Health Brussels   (Belgium)

Author keywords

Epidemiology; Pneumococcol vaccination; Streptococcus pneumoniae

Indexed keywords

ERYTHROMYCIN; OFLOXACIN; PENICILLIN G; STREPTOCOCCUS VACCINE; TETRACYCLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ASPLENIA; BELGIUM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DRUG USE; ELDERLY CARE; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY DISEASE; LIQUORRHEA; LIVER CIRRHOSIS; PRACTICE GUIDELINE; SHORT SURVEY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TRANSPLANTATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 32444435176     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2005.050     Document Type: Short Survey

References (60)

1. Peetermans W, Bachez P, Peleman R, et al. Belgian consensus on pneumococcal vaccine. Acta Clin Belg 1996; 51: 350-6.
2. Peleman RA, Peetermans WE, Van Laethem Y, et al. Prevention of pneumococcal disease: an update on the Belgian Consensus report. Acta Clin Belg 1999; 54: 321-7.
3. Peetermans WP, Lacante P. Pneumococcal vaccination by general practitioners: an evaluation of current practice. Vaccine 2000; 18: 612-7.
4. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European Countries. Clin Infect Dis 2000; 31: 444-50.
5. Jackson LA, M. Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-55.
6. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. Arch Intern Med 1994; 154: 2666-77.
7. Hutchison BG, Oxman AD, Shannon HS, et al. Clinical effectiveness of pneumococcal vaccine. Meta analysis. Can Fam Phys 1999; 45: 2381-93.
8. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Practice 2000; I: 1(1).
9. Cornu C, Yzèbe D, Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19: 4780-90.
10. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20: 2166-73.
11. Puig-Barbara J, Belenguer VA, Goterris PM, Brines Benlliure MJ. Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis. Aten Primaria 2002; 30: 269-83.
12. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochane Database Syst Rev 2004; 1.
13. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19: 353-63.
14. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22: 927-46.
15. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17: 2493-500.
16. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-90.
17. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-60.
18. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Arch Intern Med 1995; 155: 2336-40.
19. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-7.
20. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-31.
21. Christenson B, Lundbergh P, Hedlund J, Örtqvist Å. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357: 1008-11.
22. Christenson B, Lundbergh P. Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection. Epidemiol Infect 2002; 129: 515-24.
23. Hedlund J, Christenson B, Lundbergh P, Örtqvist Å. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1 -year follow-up. Vaccine 2003; 21: 3906-11.
24. Christenson B, Hedlund J, Lundbergh P, Örtqvist Å. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363-8.
25. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159: 2437-42.
26. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during the influenza seasons among elderly with chronic lung disease. Vaccine 1999; 17: S91-3.
27. Nederlandse Gezondheidsraad. Vaccinatie tegen pneumokokken bij ouderen en risicogroepen. Rapport 2003/10.
28. Schatz DV, Schinsky MF, Pais LB, et al. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998; 44: 760-6.
29. Molrine DC, Siber GR, Samra Y, et al. Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients. J Infect Dis 1999; 179: 513-7.
30. Leemans R, Harms G, Rijkers GT, Timens W. Spleen autotransplantation provides restoration of functional splenic lymphoid compartments and improves the humoral immune respons to pneumococcal polysaccharide vaccine. Clin Exp Immunol 1999; 117: 596-604.
31. Amman AJ, Addrego J, Wara DW, et al. Polyvalent pneumococcal polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 1977; 297: 897-900.
32. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE, and the Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32: 794-800.
33. López-Paloma C, Matín-Zamorano M, Benítez, et al. Pneumonia in HIV-Infected patients in the HAART era: incidence, risk, and impact of the pneumocccal vaccination. J Med Virol 2004; 72: 517-24.
34. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22: 2006-12.
35. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160: 2633-8.
36. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-11.
37. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37: 438-47.
38. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 2000; 18: 524-30.
39. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2002; 20: 545-53.
40. Goetz MB, Feikin DR, Lennox JL, et al. Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients. AIDS 2002; 16: 1421-3.
41. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34: 813-21.
42. Kazancioǧlu R, Sever ŞM, Yüksel-Önel D, et al. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin Transplant 2000; 14: 61-5.
43. Dengler TJ, Strnad N, Bühring I, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998; 66: 1340-7.
44. McCashland TM, Preheim LC, Gentry-Nielsen MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181: 757-60.
45. Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32: 307-10.
46. Stark K, Günther M, Schönfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet 2002; 359: 957-65.
47. McMahon BJ, Parkinson AJ, Bulkow L, et al. Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with non-alcoholic native and non-Native controls. Am J Med 1993; 95: 589-94.
48. Fluchshuber A, Kühnemund O, Keuth B, Lütticker R, Michalk D, Querfeld U. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996; 11: 468-73.
49. Artz AS, Erschler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16: 308-18.
50. Konradson HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995; 21: 616-20.
51. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176: 1100-4.
52. Lackner TE, Hamilton R, Hill J, Davey C, Guay DR. Pneumococcal polysaccharide revaccination: immunoglobulin G seroconversion, persistence, and safety in frail, chronically ill older subjects. J Am Geriatr Soc 2003; 51; 240-5.
53. Törling J, Hedlund J, Konradsen HB, Örtqvist Å. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103.
54. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281: 243-8.
55. Beutels P, Postma M. Economic evaluations of adult pneumococcal vaccination strategies. Expert Rev Pharmacoeconomics Outcomes Res 2001; 1: 89-100.
56. Anonymous. Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults. MMWR? 1999; 48: RR8.
57. De Wals P, Vienne A, Lemaire G, et al. Acceptabilité de la vaccination contre l'influenza. Rev Méd Brux 1989; 10: 49-52.
58. Remmen R, Seuntjens R, Vriens V, et al. Doeltreffendheid van inentingscampagnes tegen influenza. Huisarts Nu 2004; 33 (3): 147-51.
59. Flamaing J, Verhaegen J, Peetermans WE. Streptococcus pneumoniae bacteraemia in Belgium: differential characteristics in children and the elderly population and implications for vaccine use. J Antimicrob Chemother 2002; 50: 43-50.
60. Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 2003; 49: 246-50.